Join us on Facebook  |  Contact Us

Our Supporters

We would like to thank our supporters for their involvement in the event.

Platinum Supporter

Platinum Supporter

Covidien Website

Booths 23, 24, 31 and 32

Gold Supporter

Gold Supporter

Baxter Healthcare Website

Booths 33 and 34

Baxter Healthcare has invested heavily in the Australia and New Zealand (ANZ) region for over 45 years.

New Zealand operations commenced in 1980 and include a head office in Auckland; warehouse and distribution centres in Auckland and Christchurch; and aseptic compounding pharmacies in Auckland, Waikato and Christchurch.

Bronze Supporter

Bronze Supporter

GE Healthcare Website

Booth 4

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.

Bronze Supporter

Bronze Supporter

MSD Website

Booth 37

MSD NZ (formerly Merck Sharp & Dohme NZ Ltd) is a wholly owned subsidiary of Merck & Co. Inc., a global research-driven pharmaceutical company dedicated to putting patients first. Merging with Schering-Plough last year, the merger business is now known as MSD in New Zealand. Through our prescription medicines, vaccines, biologic therapies, anaesthetics, consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. For more information, visit www.merck.com

Bronze Supporter

Bronze Supporter

Mundipharma Website

Booths 15 and 16

Mundipharma is a leading provider of treatments for moderate to severe chronic pain, in New Zealand and throughout the world.

Mundipharma was established in New Zealand in 2005. We combine global experience with local knowledge and understanding to deliver a New Zealand perspective on an issue that affects 20% of the population, persistent pain*.